| HOME >> MEDICINE >> TECHNOLOGY |
Figure 12: Russia - state purchasing of drugs structure, 2010 68
Figure 13: Russia - relative sales and volume of the Russian pharmaceutical market (indexed against volume or value in 2005), 2005-09 74
Figure 14: Russia - pharmaceutical sales by therapy area (%), 2005-09 76
Figure 15: Russia - sales growth for the leading pharmaceutical brands ($m and %), 2009 80
Figure 16: Russia - sales growth for leading pharmaceutical companies (%), 2005-09 84
Figure 17: Russia - comparison of generic volume uptake versus other major pharmaceutical markets (%), 2007-08 94
Figure 18: Russia - comparison of generic value uptake versus other major pharmaceutical markets (%), 2007-08 95
Figure 19: Russia - comparison of generics market size versus other pharmaceutical markets ($ billion), 2007-08 96
Figure 20: Russia - key factors impacting generics uptake in Russia, 2010 97
Figure 21: Russia - mean erosion (by value and volume) of branded small molecules during the first 2 years of generic competition (%) 108
Figure 22: Russia - mean erosion (by value and volume) of branded small molecules by prescribing setting during the first 2 years of generic competition (%) 110
Figure 23: Russia - mean erosion (by value and volume) of branded small molecules by therapy area during the first 2 years of generic competition (%) 112
Figure 24: Russia - mean erosion (by value and volume) of branded small molecules by formulation during the first 2 years of generic competition (%) 114
Figure 25: Russia - key factors impacting biosimilars uptake in Russia, 2010 115
Figure 26: Russia - biosimilar versus branded filgrastim value uptake (%), 2006-09 118
Figure 27: Russia - biosimilar versus branded filgrastim volume uptake (%), 2006-09 119
Figure 28: Russia - sales (based on 2009 sales data) of original biologics both expired and expected to come off-pa
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |